Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Untying the Knot: What Lies Behind the Image?

Untying the Knot: What Lies Behind the Image? GUEST EDITORIAL Rivka R. Colen, MD nterrogation of cancer’s molecular and biological underpinnings important predictive and prognostic molecular markers and signal- I has transformed medicine. The knowledge gleaned from recent ing pathways of primary brain tumors are discussed along with a advances in genomics and metabolomics has provided the framework comprehensive summary of novel drugs in clinical trials and their mechanisms. Knowledge of genomics and important pathways in needed for molecular-targeted therapeutics and immunotherapies to emerge as the next-generation wave of cancer treatments. Genomic gliomas is important as we begin to understand gliomagenesis, information now serves in many instances as the patient stratification targeted therapeutics, treatment response, and patient outcomes. portal to enter specific clinical trials. Patients with histopathological Hassan et al present a systematic and thorough review on genomics similar tumors harbor genomically distinct tumors (inter-individual and noncoding RNA (microRNA and long noncoding RNA) with an heterogeneity) and a single tumor harbors intratumor niches with emphasis on glioma. The next 3 articles focus on imaging. We begin genomic dissimilarity (intratumor heterogeneity). Thus, although we with a review of imaging metabolomics by Hu et al focusing on have a deeper understanding of the cancer genesis, more questions magnetic resonance spectroscopy and hyperpolarization magnetic have arisen from precisely our vast genomic knowledge-base. Cancer resonance imaging (MRI) for evaluation of IDH1 mutation in heterogeneity remains one of the major causes to therapy failure. gliomas. This is followed by an extensive review of the literature Molecular-targeted clinical trials depend on molecular profiles from by ElShafeey et al on imaging genomics in gliomas and metastasis. a small sample obtained from a biopsy or resection that is albeit a Finally, Abroletalofferadetailed review on radiomics and a brief small snapshot of the entire tumor. On the contrary, imaging is a discussion on big data; an in-depth breakdown of the radiomic noninvasive method that can interrogate the entire 3-dimensional workflow and pipeline is provided. tumor or tissue. The advent of high computational power now allows I would like to thank and recognize all the authors, experts in us to sequence entire genomes at speeds not thought possible their respective fields, for contributing their knowledge to assemble previously; this has yielded a plethora of rich information of cancers’ some of the most cutting-edge topics in imaging, genomics, signaling genome. Along the same line, high computation power and large pathways, and metabolomics to make this edition a success. I hope database storage capabilities coupled with machine learning tech- the readers find this edition very insightful. niques and artificial intelligence have enabled automated high- I would like to thank Dr. Scott Atlas, Editor-in-Chief, for throughput image feature extraction such as those leveraged with inviting me to be the guest editor of this innovative issue. Some radiomics as well as making sense of what has been termed ‘‘big of the emerging topics in the medical field, in particular as it relates to data.’’ Thus, this issue of Topics in MRI tries to bring together imaging, are highlighted in this issue. In addition, I express my various novel subject matters for the radiologist. immense gratitude to the editorial staff Samantha Martin, editorial This edition commences with the first 2 articles focusing on coordinator, and Stella Bebos, Associate Publisher, for their work on signaling pathways and genomics in brain tumors; the subsequent getting this issue out and in print. last 3 articles focus on imaging metabolomics, imaging genomics, Finally, I would like to dedicate this issue to my lovely daughter, and radiomics. We begin this issue with an in-depth review by Mila Rayne Alondra Zinn, and my supportive and loving husband, Harrison and de Groot on signaling pathways in brain tumors; Pascal O. Zinn, MD, PhD. Life together is a beautiful journey. From the Department of Diagnostic Radiology and Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX. Address correspondence to Rivka R. Colen, MD, Department of Diagnostic Radiology and Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1482, Rm #FCT 16.5037, Houston, TX 77030. E-mail: rcolen@mdanderson.org. Funding source: CCSG P30 CA-16672. The authors report no conflicts of interest. Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/RMR.0000000000000116 Topics in Magnetic Resonance Imaging  Volume 26, Number 1, February 2017 www.topicsinmri.com 1 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Topics in Magnetic Resonance Imaging Wolters Kluwer Health

Untying the Knot: What Lies Behind the Image?

Colen, Rivka R.
Topics in Magnetic Resonance Imaging , Volume 26 (1) – Feb 1, 2017
Download PDF
1 page

Loading next page...
 
/lp/wolters-kluwer-health/untying-the-knot-what-lies-behind-the-image-hM8y9teKGV

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0899-3459
eISSN
1536-1004
DOI
10.1097/RMR.0000000000000116
pmid
28157828
Publisher site
See Article on Publisher Site

Abstract

GUEST EDITORIAL Rivka R. Colen, MD nterrogation of cancer’s molecular and biological underpinnings important predictive and prognostic molecular markers and signal- I has transformed medicine. The knowledge gleaned from recent ing pathways of primary brain tumors are discussed along with a advances in genomics and metabolomics has provided the framework comprehensive summary of novel drugs in clinical trials and their mechanisms. Knowledge of genomics and important pathways in needed for molecular-targeted therapeutics and immunotherapies to emerge as the next-generation wave of cancer treatments. Genomic gliomas is important as we begin to understand gliomagenesis, information now serves in many instances as the patient stratification targeted therapeutics, treatment response, and patient outcomes. portal to enter specific clinical trials. Patients with histopathological Hassan et al present a systematic and thorough review on genomics similar tumors harbor genomically distinct tumors (inter-individual and noncoding RNA (microRNA and long noncoding RNA) with an heterogeneity) and a single tumor harbors intratumor niches with emphasis on glioma. The next 3 articles focus on imaging. We begin genomic dissimilarity (intratumor heterogeneity). Thus, although we with a review of imaging metabolomics by Hu et al focusing on have a deeper understanding of the cancer genesis, more questions magnetic resonance spectroscopy and hyperpolarization magnetic have arisen from precisely our vast genomic knowledge-base. Cancer resonance imaging (MRI) for evaluation of IDH1 mutation in heterogeneity remains one of the major causes to therapy failure. gliomas. This is followed by an extensive review of the literature Molecular-targeted clinical trials depend on molecular profiles from by ElShafeey et al on imaging genomics in gliomas and metastasis. a small sample obtained from a biopsy or resection that is albeit a Finally, Abroletalofferadetailed review on radiomics and a brief small snapshot of the entire tumor. On the contrary, imaging is a discussion on big data; an in-depth breakdown of the radiomic noninvasive method that can interrogate the entire 3-dimensional workflow and pipeline is provided. tumor or tissue. The advent of high computational power now allows I would like to thank and recognize all the authors, experts in us to sequence entire genomes at speeds not thought possible their respective fields, for contributing their knowledge to assemble previously; this has yielded a plethora of rich information of cancers’ some of the most cutting-edge topics in imaging, genomics, signaling genome. Along the same line, high computation power and large pathways, and metabolomics to make this edition a success. I hope database storage capabilities coupled with machine learning tech- the readers find this edition very insightful. niques and artificial intelligence have enabled automated high- I would like to thank Dr. Scott Atlas, Editor-in-Chief, for throughput image feature extraction such as those leveraged with inviting me to be the guest editor of this innovative issue. Some radiomics as well as making sense of what has been termed ‘‘big of the emerging topics in the medical field, in particular as it relates to data.’’ Thus, this issue of Topics in MRI tries to bring together imaging, are highlighted in this issue. In addition, I express my various novel subject matters for the radiologist. immense gratitude to the editorial staff Samantha Martin, editorial This edition commences with the first 2 articles focusing on coordinator, and Stella Bebos, Associate Publisher, for their work on signaling pathways and genomics in brain tumors; the subsequent getting this issue out and in print. last 3 articles focus on imaging metabolomics, imaging genomics, Finally, I would like to dedicate this issue to my lovely daughter, and radiomics. We begin this issue with an in-depth review by Mila Rayne Alondra Zinn, and my supportive and loving husband, Harrison and de Groot on signaling pathways in brain tumors; Pascal O. Zinn, MD, PhD. Life together is a beautiful journey. From the Department of Diagnostic Radiology and Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX. Address correspondence to Rivka R. Colen, MD, Department of Diagnostic Radiology and Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1482, Rm #FCT 16.5037, Houston, TX 77030. E-mail: rcolen@mdanderson.org. Funding source: CCSG P30 CA-16672. The authors report no conflicts of interest. Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/RMR.0000000000000116 Topics in Magnetic Resonance Imaging  Volume 26, Number 1, February 2017 www.topicsinmri.com 1 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

Journal

Topics in Magnetic Resonance Imaging – Wolters Kluwer Health

Published: Feb 1, 2017

There are no references for this article.